Lupin to present phase 1 data on LNP3693 at the ESMO Congress 2025: Our Bureau, Mumbai Monday, October 13, 2025, 16:30 Hrs [IST] Global pharma major Lupin Limited (Lupin) will pre ...
13d
Lupin Announces Presentation of Phase 1 Data on LNP3693 (STING agonist) at the ESMO Congress 2025
MUMBAI, India and NAPLES, Fla. and BERLIN, Oct. 13, 2025 /PRNewswire/ -- Global pharma major Lupin Limited (Lupin) (BSE: ...
PHOENIX--(BUSINESS WIRE)--Faculty and graduate students with the University of Phoenix College of Doctoral Studies joined the proceedings of The Qualitative Review (TQR) 16th Annual Conference. The ...
LNP3693 is an investigational parenteral STING agonist. The presentation will provide qualitative insights into its safety, pharmacokinetics, pharmacodynamics, and preliminary anti-tumor activity in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback